

HALOZYME THERAPEUTICS INC

Form 4/A

August 07, 2007

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Frost Gregory Ian2. Issuer Name **and** Ticker or Trading  
Symbol  
HALOZYME THERAPEUTICS  
INC [HALO]5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
08/02/2007☐ X Director ☐ 10% Owner  
☒ X Officer (give title below) ☐ Other (specify below)  
VP and Chief Scientific Off.C/O HALOZYME  
THERAPEUTICS, INC., 11588  
SORRENTO VALLEY ROAD,  
SUITE 17

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)  
08/03/20076. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ X Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

SAN DIEGO, CA 92121

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        |                  | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|--------|------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|                                 |                                      |                                                    | Code                           | V                                                                 | Amount | (A) or (D) Price |                                                                                               |                                                          |                                                       |
| Common Stock                    | 08/02/2007                           |                                                    | S <sup>(1)</sup>               |                                                                   | 1,701  | D \$ 7.99        | 2,980,506                                                                                     | D                                                        |                                                       |
| Common Stock                    | 08/02/2007                           |                                                    | S <sup>(1)</sup>               |                                                                   | 6,438  | D \$ 8           | 2,974,068                                                                                     | D                                                        |                                                       |
| Common Stock                    | 08/02/2007                           |                                                    | S <sup>(1)</sup>               |                                                                   | 474    | D \$ 8.01        | 2,973,594                                                                                     | D                                                        |                                                       |
| Common Stock                    | 08/02/2007                           |                                                    | S <sup>(1)</sup>               |                                                                   | 1,288  | D \$ 8.03        | 2,972,306                                                                                     | D                                                        |                                                       |

# Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4/A

|              |            |                  |       |   |         |           |   |
|--------------|------------|------------------|-------|---|---------|-----------|---|
| Common Stock | 08/02/2007 | S <sup>(1)</sup> | 1,800 | D | \$ 8.04 | 2,970,506 | D |
| Common Stock | 08/02/2007 | S <sup>(1)</sup> | 900   | D | \$ 8.05 | 2,969,606 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3) |
|--------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                            |                                                        |                                      |                                                    | Code                           | V (A) (D)                                                                               | Date Exercisable                                         | Expiration Date                                               | Title                                      | Amount or Number of Shares                                                                      |

## Reporting Owners

| Reporting Owner Name / Address                                                                                      | Relationships                    |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------|
|                                                                                                                     | Director 10% Owner Officer Other |
| Frost Gregory Ian<br>C/O HALOZYME THERAPEUTICS, INC.<br>11588 SORRENTO VALLEY ROAD, SUITE 17<br>SAN DIEGO, CA 92121 | X VP and Chief Scientific Off.   |

## Signatures

/s/ Gregory I. Frost 08/07/2007

Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4/A

(1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

**Remarks:**

This Form 4/A replaces in its entirety the second Form 4 that was filed on 8/3/07 (Acc-no: 0001380444-07-000026). The first

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.